Results of a recent systematic review and meta-analysis of cannabidiol’s (CBD’s) efficacy in reducing seizure frequency in patients with pharmacoresistant epilepsy were encouraging, but further research is needed.
Epilepsy affects an estimated 50 million people around the world. Beyond seizures, it can cause serious impairments for some individuals with the syndrome. While around 80% of epilepsy cases can be treated effectively with monotherapy (the use of a single drug), 20% of patients are pharmacoresistant. This means adequate seizure control cannot be achieved with two or more relevant antiepileptic drugs. In extreme cases, some patients may continue to experience thousands of seizures each month. Other terms used for this situation are refractory, drug-resistant or intractable epilepsy.
Source: https://hempgazette.com/news/cbd-seizure-control-hg2438/